{"id":243,"date":"2024-02-21T13:36:21","date_gmt":"2024-02-21T11:36:21","guid":{"rendered":"https:\/\/webs.uab.cat\/therCNS\/?page_id=243"},"modified":"2024-03-11T18:35:35","modified_gmt":"2024-03-11T16:35:35","slug":"linea-3-m","status":"publish","type":"page","link":"https:\/\/webs.uab.cat\/therCNS\/linea-3-m\/","title":{"rendered":"Design, generation and production of AAV and adenovirus vectors"},"content":{"rendered":"\n
\n

The research group has large experience in the design, development, generation, production, and characterization of AAV and adenovirus vectors at preclinical level<\/strong>, demonstrated by a significant number of scientific articles in gene therapy, granted projects, patents and in the creation of 2 spin-off companies in gene therapy. <\/p>\n<\/blockquote>\n\n\n\n

With 30 years of experience in AAV and adenovirus vectors, our research group has the capacity to generate a wide range of different viral vectors, a proven track record in both preclinical and clinical studies, as well as an active research and development lines for procedure optimization and construction of AAV vector libraries. As a result, our group is one of the only 6 gene therapy groups participating in the Network of Excellence on Advanced Therapies (RICORS-TERAV) financed by the Instituto de Salud Carlos III (ISCIII). <\/p>\n\n\n\n

Vector Production Unit -UPV-<\/h2>\n\n\n\n
\n

The technological advances on gene therapy vectors generated and\/or set up by the research group are implemented into the UPV<\/a><\/strong>, a technological Platform created by our research group, which is specialized in the cloning, production and purification of adenovirus and adeno-associated virus (AAV) serotypes for public institutions and private companies all over the world (more than 2000 batches in the last years).<\/p>\n<\/blockquote>\n\n\n\n

\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

In addition to Laboratories NSB1 and NSB2, our research group has a Biosafety Level 3 laboratory, allowing work with the SARS-CoV-2 coronavirus. This has enabled collaborations and contracts for projects involving the manipulation of SARS-CoV-2 and the development of various COVID-19-related products such as diagnostic kits, vaccines, and disinfection protocols.<\/p>\n<\/div>\n<\/div>\n\n\n\n

To highlight that the UPV<\/a> has a quality assurance system compliant with ISO 9001:2015 requirements since August 23, 2018. It also holds the TECNIO Quality accreditation from the Generalitat de Catalunya since 2018.<\/p>\n","protected":false},"excerpt":{"rendered":"

The research group has large experience in the design, development, generation, production, and characterization of AAV and adenovirus vectors at preclinical level, demonstrated by a significant number of scientific articles in gene therapy, granted projects, patents and in the creation of 2 spin-off companies in gene therapy. With 30 years of experience in AAV and […]<\/p>\n","protected":false},"author":2848,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-243","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/243","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/users\/2848"}],"replies":[{"embeddable":true,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/comments?post=243"}],"version-history":[{"count":12,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/243\/revisions"}],"predecessor-version":[{"id":953,"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/pages\/243\/revisions\/953"}],"wp:attachment":[{"href":"https:\/\/webs.uab.cat\/therCNS\/wp-json\/wp\/v2\/media?parent=243"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}